Clinical Trial

Dapagliflozin in Allo-HCT for aGVHD

Study acronym: DAPALAG-01
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 5, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-02
Trial Details
NCT Number NCT06626737
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Graft-versus-host Disease (GVHD)
Enrollment 72 participants
Start Date 2025-04-26
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-05